Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lutetium Lu 177 Rosopatamab Tetraxetan

Radiopharmaceutical · Cytotoxic, directed at prostate-specific membrane antigen (FOLH1) · developed by Telix Pharmaceuticals Pty

Phase 2 Most advanced trial (none active)

TLX Developer

1 Registered trials

What is Lutetium Lu 177 Rosopatamab Tetraxetan?

Lutetium Lu 177 rosopatamab tetraxetan is a radioimmunoconjugate consisting of a humanized monoclonal antibody against prostate-specific membrane antigen (PSMA) linked to the beta-emitting radioisotope lutetium Lu 177. It binds to PSMA-expressing tumor cells and delivers cytotoxic beta radiation. The drug is studied in prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: 177Lu-DOTA-TLX591
Drug type: Radiopharmaceutical
Targets: prostate-specific membrane antigen (FOLH1)
Mechanism: Cytotoxic, directed at prostate-specific membrane antigen (FOLH1)
Therapy area: Oncology
Developer: Telix Pharmaceuticals Pty Limited (TLX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05146973	Phase 2	Prostate Cancer	Completed	TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostate Cancer

Other drugs acting on FOLH1

Gallium Ga 68 Gozetotide FDA approved ES414 Phase 1

More from Telix Pharmaceuticals Pty

177Lu girentuximab Phase 1/2 177Lu-TLX591 Phase 3 89Zr-DFOsq-olaratumab Phase 1 Copper Cu 64-DOTA-TLX592 Early Phase 1 Iodine I 131 IPA Phase 1 Samarium Sm 153-DOTMP Phase 1 Zirconium Zr 89 Girentuximab Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TLX page.

Follow TLX, the company behind Lutetium Lu 177 Rosopatamab Tetraxetan

See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z